Cohort
Members of the American Society of Pediatric Hematology/Oncology (ASPHO)
Vascular Anomalies Special Interest Group (VA SIG) were invited to
participate by submitting clinical data of patients diagnosed with
KHE/TA between January 2005 and January 2020 with at least 6 months of
follow-up. Subjects who died within 6 months of diagnosis and met all
other eligibility criteria were included. This study was IRB approved at
each local institution, and patient clinical and treatment information
was collected securely in a REDCap database.29 Data
from each center, excluding protected health information, were
adjudicated by Drs. Borst, Jeng, and Adams and sent to the coordinating
center for analysis.